Omicron, BioNTech: “Vaccines starting from October”

In addition to the one updated to BA.1, the company and Pfizer also start testing on a product adapted to Omicron 4 and 5

Covid vaccines adapted to Omicron starting from October. This is the goal communicated today by the German BioNTech which, announcing the financial results for the second quarter and the first half of 2022, took stock of the programs it is carrying out together with the American Pfizer on the front of the fight against Sars-CoV. -2. In addition to the bivalent vaccine based on the original virus and on Omicron BA.1, for which the green light has already been requested from the European Medicines Agency Ema, the two companies intend to launch clinical trials this month on a bivalent vaccine targeting Omicron BA.4 and BA.5. For both products “we expect to be able to start supplying vaccines adapted to Omicron as early as October, subject to regulatory approval,” informs BioNTech.

In the first half of 2022, compared to the first 6 months of 2021, the company based in Mainz recorded sales up 30% to 9.57 billion euros and a net profit up 37% to 5.37 billion euros. In the second quarter of the year, compared to the same period of the previous year, both sales and net profit show a decline of approximately 40%, to 3.2 billion and 1.67 billion respectively. BioNTech attributes this to the “dynamic development of the pandemic, leading to a postponement of orders and therefore to fluctuations in quarterly sales”. However, the group confirms the year-end targets, with sales of Covid-19 vaccines ranging between 13 and 17 billion euros.